ALOK SINGH B.PHARM 3rd year 1507850005

1. DR. K.N.M.I.P.E.R.
MODINAGAR
SOLID LIPID
NANOPARTICLE(SLNs)
Presented by
ALOK SINGH
B.Pharm 3rd
year
1507850005

2. NANOPARTICLES
 Nanoparticles are particles between 1 and
100 nanometres (nm) in size with a surrounding
interfacial layer.
 The interfacial layer is an integral part of
nanoscale matter, fundamentally affecting all of
its properties.
 The interfacial layer typically consists of ions,
inorganic and organic molecules.
 Organic molecules coating inorganic
nanoparticles are known as stabilizers, capping
and surface ligands.

3. TYPES OF NANOPARTICLES
 Polymeric Micelles
 Nanosuspension and Nanocrystals
 Ceramic NPs
 Liposomes
 Niomoses
Solid-Lipid Nanoparticles
 Dendrimers
 Magnetic Nanoparticles

4. DIFFERENT NANOPARTICLES

5. SOLID LIPID NANOPARTICLE
 Solid-lipid Nanoparticles (SLNs) are submicron
colloidal carriers composed of a single lipid core
matrix that is solid at body temperature, and is
coated with a surfactant acting as stabilizer.
 A solid lipid nanoparticle is typically spherical with -an
average diameter between 10 and 1000 nanometers.
 Solid lipid nanoparticles possess a solid lipid core
matrix that can solubilize lipophilic molecules.
 The lipid core is stabilized by surfactants (emulsifiers).
 The term lipid is used here in a broader sense and
includes Mono , Di and Triglycerides, fatty
acids , steroids and waxes .
 All classes of emulsifiers have been used to stabilize the

6. STRUCTURE

7. TYPES OF SOLID LIPID NANOPARTICLES
SLNs can be divided into 3 basic types on the basis of drug
loading:-
I. Type-1(homogeneous matrix model)
II. Type-2(drug enriched shell model)
III.Type-3(drug enriched core model)
drugdrug

10. 1. HIGH PRESSURE HOMOGENIZATION

12. ADVANTAGES
 The SLNs bypass liver and spleen filtration.
 Controlled release of the incorporated drug can be achieved
for up to several weeks .
 SLN formulations stable for even three years has been
developed.
 The feasibility of incorporating both hydrophilic and
hydrophobic drugs .
 The carrier lipids are biodegradable and hence safe .
 Generally less toxic as compared to some polymeric
nanoparticles because physiological and biocompatible lipids
are used .
 Protecting the labile and sensitive drugs from chemical,
photochemical or oxidative degradation, due to
immobilization of drug molecules by solid lipids .

13. DISADVANTAGES
 Poor drug loading capacity.
 Drug expulsion during storage.
 Low capacity to load Hydrophilic drugs due to
partitioning effect during production procss.
 Particle growth.

14. USES/APPLICATIONS OF SLNS